Mineralys Therapeutics, Inc. announced its financial results for Q4 2025, highlighting a significant cash position of $656.6 million and the FDA's acceptance of its NDA for lorundrostat, targeting hypertension. The company plans a conference call to discuss these developments.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.